儿童脑干活检的安全性与技术有效性:对1000余名儿童的更新Meta分析
该Meta分析纳入2003至2023年间29项儿童脑干活检研究、共1002名儿童,采用随机效应模型合并比例。活检组织学诊断率为96.8%(95%CI 95.4-98.2),暂时性并发症6%(95%CI 4-8),永久性并发症1%(95%CI 0.5-2),死亡5例(0.5%)。作者认为向家属说明永久性并发症罕见(<2%)是合理的。
要点
- 儿童脑干活检组织学诊断率96.8%(95%CI 95.4-98.2)。
- 暂时性并发症6%(95%CI 4-8),永久性并发症1%(95%CI 0.5-2)。
- 1002名儿童中报告死亡5例(0.5%)。
核心结论
- 向家属说明儿童脑干活检永久性并发症罕见(<2%)是合理的。
- 若活检专为满足需分子诊断的临床试验入组而做,应将本文所述活检风险与入组潜在获益权衡。
研究设计与样本
- 纳入近20年(2003-2023年)29项儿童脑干活检研究,共1002名儿童。
- 采用随机效应模型对比例进行Meta分析,生成点估计、置信区间和异质性指标。
主要发现
- 87%的操作方式为立体定向穿刺活检,其中62%使用头架、14%不使用头架、24%为机器人辅助。
- 活检获得组织学诊断(技术产出率)为96.8%(95%CI 95.4-98.2)。
- 暂时性并发症为6%(95%CI 4-8),最常见神经系统并发症为颅神经功能障碍、共济失调加重或新发、肢体无力。
- 永久性并发症(不含死亡)为1%(95%CI 0.5-2),最常见包括颅神经功能障碍和肢体无力。
- 整个1002名儿童合并队列中报告死亡5例(0.5%)。
临床怎么用
- 作者认为,向家属说明儿童脑干活检永久性并发症罕见(<2%)是合理的。
- 作者认为,若活检专为满足需分子诊断的临床试验入组而做,应将本文所述活检风险与入组潜在获益权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brainstem tumors represent ∼10% of pediatric brain tumors, ∼80% of these are diffuse midline glioma. Given invariably poor prognosis in diffuse midline glioma, there continues to be immense variation worldwide in performing biopsy of these lesions. Several contemporary studies in recent years have provided new data to elucidate the safety profile of biopsy and an updated meta-analysis is thus indicated. METHODS: We found 29 studies of pediatric brainstem biopsy in the last 20 years (2003-2023, 1002 children). We applied meta-analysis of proportions using a random-effects model to generate point estimates, confidence intervals, and measures of heterogeneity. RESULTS: Eighty-seven percent of procedures were stereotactic needle biopsies (of these, 62% with a frame, 14% without frame, and 24% robotic.) Biopsy resulted in a histological diagnosis ("technical yield") in 96.8% of cases (95% CI 95.4-98.2). Temporary complications were seen in 6% (95 CI 4-8), with the most common neurological complications being 1) cranial nerve dysfunction, 2) worsening or new ataxia, and 3) limb weakness. Permanent complications (excluding death) were seen in 1% (95% CI 0.5-2), most commonly including cranial nerve dysfunction and limb weakness. Five deaths were reported in the entire pooled cohort of 1002 children (0.5%). CONCLUSIONS: When counseling families on the merits of brainstem biopsy in children, it is reasonable to state that permanent morbidity is rare (<2%). If biopsy is performed specifically to facilitate enrollment in clinical trials requiring a molecular diagnosis, the risks of biopsy outlined here should be weighed against potential benefits of trial enrollment.
引用
- Sheikh SR, Patel NJ, Recinos VMR, et al. Safety and Technical Efficacy of Pediatric Brainstem Biopsies: An Updated Meta-Analysis of 1000+ Children. World Neurosurg. 2024. PMID: 38968995. doi:10.1016/j.wneu.2024.06.163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。